Articles tagged with Cancer Medication
Researchers at the University of Minnesota have discovered a novel class of tumor-targeting compounds that inhibited tumor growth by up to 80 percent in animal studies. The compounds, designed to mimic anti-angiogenic proteins, show promise in treating solid and liquid tumors, including those found in leukemia and other blood cancers.
Researchers discover that a specific gene mutation increases gene activity to speed up the internal clock, contrary to previous beliefs. This finding has significant implications for developing treatments for circadian rhythm disorders such as depression and insomnia.
The drug, Dz13, targets c-Jun, a master regulator gene involved in diseases such as cancer and inflammation. In pre-clinical models, it has shown effectiveness in treating skin cancers and eye diseases like AMD.
The publication of consensus recommendations for FDG PET usage is expected to reduce variability in clinical trials, leading to shorter trials and improved treatment outcomes. The guidelines provide a valuable reference for incorporating PET into clinical trials and promoting drug development.
The Lancet highlights the case of CancerBACUP, a UK charity that accepted funding from drug manufacturer for trastuzumab, yet failed to disclose this in press releases. The charity's failure undermines its credibility and raises questions about its true interests.
The HHMI Physician-Scientist Early Career Award program provides flexible funding and time for young physicians to pursue research careers. Thirteen awardees have made impressive contributions to various fields, including genomics, proteomics, and cancer research.
Researchers found that a gene-regulating enzyme is targeted by certain monoamine oxidase inhibitors used to treat depression. These drugs, such as tranylcypromine, may also have anti-cancer activity due to their ability to inhibit the growth of cancer cells.
The introduction of Gardasil in the USA is proving problematic due to social and cultural resistance. The Bill and Melinda Gates Foundation has donated $27.7 million to PATH to research introducing the vaccine in developing countries, where Merck and GSK can assist by identifying cultural barriers.
A study by Johns Hopkins Medicine found that tracking computer-based error reports can improve patient safety. The researchers analyzed 1,010 medication errors and found that nearly one-third of all errors occurred with anti-infective medications.
Sheryl Tsai receives $240,000 to pursue her work on polyketide synthases, enzymes that produce natural products used in pharmaceuticals. Her research aims to develop new drugs for cancer and other diseases.
Scientists at Rice University and M.D. Anderson Cancer Center have developed a method to load multiple anticancer drugs into a single antibody, increasing the effectiveness of chemotherapy. The use of buckyballs, soccer ball-shaped molecules of pure carbon, allows for the creation of targeted therapeutics with unique properties.
A new nationwide study found that cyclophosphamide improved breathing, lung function, quality of life, functional disability, and skin thickness in patients with scleroderma. The findings will help researchers develop new drug therapies and better understand the disease's development.
Researchers found that a single dose of Taxol had induced significant testicular weight loss compared to the control group. However, an injection of AS101 a day before Taxol prevented this damage. The study suggests that immune reaction to treatment causes additional testicular damage.
Researchers found Sprycel to be extremely effective in combating Gleevec resistance, with a major cytogenetic response reported in 45% of chronic phase patients. The drug works by binding to mutant proteins and inhibiting tyrosine kinases, offering CML patients a new treatment option.
Dasatinib successfully circumvents Gleevec resistance in 68 of 84 patients, providing new options for CML treatment. The drug works in advanced stages of the disease and shows durable responses with no serious side effects.
A phase I clinical trial reveals nilotinib has a relatively favorable safety profile and demonstrates activity against drug-resistant CML, with notable improvements in chronic phase CML patients. However, the agent shows less activity in acute lymphoblastic leukemia patients and may require careful monitoring for cardiac events.
Researchers at UC Davis have identified a peptide that targets malignant lymphocytes, distinguishing it from healthy ones. The peptide, LLP2A, has the potential to be used as an imaging agent for patients with lymphoid cancers, offering a more targeted approach than existing monoclonal antibodies.
Researchers found that a new drug, imatinib, destroys the blood vessels that feed prostate cancer cells, preventing tumor growth and metastasis. In a mouse model, tumors were significantly reduced when treated with a combination of imatinib and chemotherapy.
Researchers discovered that overexpressing a gene called uPA in mammary cancer cells can delay tumor progression and inhibit the formation of new blood vessels, leading to slower tumor growth. The study also suggests that uPA expression may have anti-cancer effects by reducing angiogenesis and proliferation.
A study found that cancer drug ads are often difficult to read, prioritizing effectiveness over safety. The ads typically featured large text highlighting benefits, with side effects and risks presented in smaller font.
The St. Jude program in Brazil reduced abandonment rates from 16% to 0.6% and increased event-free survival from 32% to 63%, providing continuous care and psychosocial support to families. The program's success is a model for reducing disparities in cure rates between high- and low-income countries.
A Phase 3 trial shows Xcytrin significantly prolongs time to neurologic progression in patients with non-small cell lung cancer and brain metastases. Xcytrin, a texaphyrin-based drug, enhances cancer cell death when combined with radiation.
A new approach to improving cancer chemotherapy involves giving anticancer drugs basic properties, allowing them to accumulate in both normal and malignant cells. This approach may lead to more effective treatment with fewer side effects.
Studies have shown that glycerrhetinic acid and glycerrhizic acid, found in liquorice, preferentially accumulate in the liver and can target tumors effectively. This could lead to improved treatment outcomes with reduced toxic effects on other parts of the body.
Researchers have found a promising new treatment for children with metastatic Gastrointestinal Stromal Tumor (GIST) that is resistant to imatinib. The therapy, sunitinib, has shown significant decreases in tumor-related activity and complete remission in some patients.
A new study by Dr. Ramalingam found that adding the drug vorinostat to standard chemotherapy improved outcomes for patients with advanced non-small cell lung cancer, with partial responses in 11 patients and disease stabilization in 7 more. The recommended dose of 400mg daily for two weeks was well-tolerated.
A new combination therapy after surgery has improved survival rates for pancreatic cancer patients by 50%, increasing median survival from 16.9 to 20.6 months. The study found significant benefits for patients with pancreatic head adenocarcinoma, a type of cancer that affects the pancreas.
A phase-2 clinical trial found that Pfizer's oral drug, sunitinib malate, showed activity similar to other approved agents for non-small cell lung cancer, resulting in six confirmed partial responses and disease stabilization in 27 patients. The study also explored the effectiveness and safety of a continuous dosing strategy.
A five-year study confirms Gleevec's effectiveness in treating Gastrointestinal Stromal Tumor (GIST), with 84% of participants showing clinical improvement. The treatment has durable benefits, with two patients experiencing complete remission, despite some developing resistance.
Research reveals genetic variants in genes involved in anthracyclines' metabolism increase risk of congestive heart failure (CHF) in childhood cancer survivors. The study suggests personalized treatment plans may be developed using gene classification to reduce toxic side effects.
Apo2L/TRAIL, a new cancer drug, has shown activity in treating advanced cancers with minimal side effects. The agent selectively induces programmed cell death in cancer cells while sparing normal cells, offering hope for targeted treatment options.
A study led by Michael C. Heinrich, M.D., found that patients with gastrointestinal stromal tumor (GIST) responded differently to Sunitinib depending on their tumor's genetic abnormality. The research highlights the importance of personalized medicine in cancer treatment.
A five-year update from the IRIS Study Group shows excellent results for people with Chronic Myelogenous Leukemia (CML) treated with Gleevec, a targeted cancer therapy. Overall survival rates reach 89% at five years, with fewer than 1% of patients progressing to accelerated or blast crisis phases.
Researchers at UC Davis Cancer Center report a significant extension of survival in advanced lung cancer patients treated with bortezomib plus standard care. The median overall survival was 11 months, with one-year survival at 46%, offering promising results for this patient population.
Researchers have discovered a zinc finger protein that can be inhibited when exposed to a platinum complex, offering new hope for the development of targeted HIV and cancer therapies. This breakthrough could lead to more specific and effective treatments with reduced side effects.
Dan David Prize winners Dr. Mendelsohn and Dr. Schlessinger were recognized for their groundbreaking research on cancer treatment and signal transduction. Their work has led to the development of effective therapies and treatments for various forms of cancer.
A phase 3 clinical study found that nearly half of patients with advanced illness experienced laxation within four hours of receiving methylnaltrexone, and over 70% responded by the end of the first week. The treatment also showed no diminishment of analgesia due to medication.
The Lancet comments on the FDA's delay in approving Plan B, an emergency contraceptive. The agency's failure to make a decision undermines its credibility. The acting FDA commissioner is urged to move swiftly and show independence.
Researchers at Northwestern University have developed a new method to deliver antisense cancer drugs using gold nanoparticles, outperforming conventional agents. The nanoparticles improve stability, binding efficiency, and cellular uptake of the DNA, resulting in enhanced gene knockdown and lower toxicity.
Researchers engineered mice with mutated EGFR genes that can be turned on or off to study lung tumorigenesis and treatment responses. Mutations in EGFR drive lung tumors into regression by inhibiting the gene or turning it off.
The IU Cancer Center will attract top-tier scientists and physicians with the gift, enhancing its national reputation as a leader in cancer research and patient care. The center's research and clinical programs are expanding, and partnerships are increasing to achieve goals.
A study found that patients with rheumatoid arthritis treated with TNF-blocking antibodies are at a higher risk of developing cancer and serious infections. The drugs, which were previously thought to be safe, may interfere with the body's ability to fight off infection and cancer.
Scientists discover a new compound, PI-103, that effectively inhibits the spread of brain cancer by targeting two separate steps in the signaling pathway. This dual blockade proves to be safe and effective in slowing down cancer cell proliferation in mice with human glioma cells.
The National Institute of Standards and Technology (NIST) will develop a measurement assessment material for proteins, mimicking human plasma proteome complexity. This collaboration aims to evaluate existing proteomic technologies, develop new ones, and establish reliable measurement tools for cancer research.
Researchers successfully transplanted white blood cells from cancer-resistant mice into normal mice, eradicating existing and preventing lethal doses of new aggressive cancers. This breakthrough study demonstrates the potential for cancer-resistant-cell therapy to treat highly aggressive types of cancer.
Researchers have identified a stomach receptor for Helicobacter pylori, a common gut bacteria that causes peptic ulcers and gastric cancer. The discovery suggests that drugs targeting this receptor could prevent or treat these diseases.
Researchers found that inhibiting myosin light chain kinase with ML-7 induces cell suicide in breast and prostate cancer cells. Combination with etoposide treatment reduces tumor growth by 88.5% and 79.1%, offering new target for cancer therapies.
Fenretinide has been shown to reduce the risk of second breast cancers in young women, particularly those under 40. The study found a 38% reduction in second breast cancers in pre-menopausal women and halved the risk for women under 40.
A preliminary study found that combining chemotherapy with the arthritis drug etanercept increased tolerance to higher doses and reduced patient fatigue. The treatment blocks tumor necrosis factor, a substance promoting tumor growth instead of hindering it.
Dr. Horwitz's research on paclitaxel's mechanism of action led to its development and approval for treating various tumor types. She now focuses on overcoming drug resistance, a major challenge in cancer treatment.
Researchers create computer algorithms to verify connection between material delivery and fluid pressure, potentially increasing chemotherapy success rate. The method may be used before chemotherapy begins to determine if high fluid pressure could render treatment ineffective.
Researchers found that cancer treatment effectiveness is independent of tumor type, and varying levels of specific proteins determine drug response. This study suggests a new approach to treating cancer by selecting therapies tailored for individual patients instead of one-size-fits-all approaches.
Researchers discovered that p110 alpha controls insulin signals, frequently mutated in cancer, but mice with a single mutation showed no signs of developing diabetes. The findings have immediate implications for testing p110 alpha-specific inhibitors for human therapies.
Researchers have developed a nano-particle system that targets and kills cancer cells using a combination of paclitaxel and doxorubicin. This innovative approach overcomes the challenge of delivering multiple drugs to tumors efficiently.
Researchers have identified a potential new treatment for malignant gliomas using bortezomib, which targets the NF-kB pathway to induce cell death. This discovery builds on previous studies showing that selective estrogen receptor modulators (SERMs) can also induce cell death in brain cancers.
Researchers identify mutation in JAK2 signaling pathway, allowing cells to bypass normal red blood-cell production process. This discovery could lead to the development of targeted treatments that improve treatment outcomes for patients with PV disease.
Strobel's program will be an introductory science course with hands-on learning, challenging students to think like working scientists. Students will collect natural products, purify and analyze compounds, and test their potential benefits.
Researchers applied engineering tools to study cell decision-making in cancer and inflammatory diseases. The studies uncovered a surprising link between the two, suggesting new treatment approaches for debilitating conditions like rheumatoid arthritis.
Experts warn that non-compliance with treatment is a major issue among teenage cancer patients, who are at high risk due to poorer prognosis rates. Improving communication skills and addressing barriers such as family support and information overload can help increase adherence.
Experts warn that doctors must discuss future fertility with young cancer patients to provide truly informed consent. Current data indicate room for improvement in fertility counselling, with only 34% of patients receiving pre-treatment advice.